 |
|
Depression and cardiovascular disease
October 16, 2007Depression has long had a popular link to cardiovascular disease and death. However, only during the last 15 years scientific evidence supporting this common wisdom has been available (Glassman et al., 2007a). Since the early 1990s studies have reported prevalences of major depression between 17% and 27% in hospitalized patients with coronary artery disease (CAD) (Rudisch & Nemeroff, 2003).
It is becoming clear that the comorbidity of depression and cardiovascular disease does not occur by chance but the mechanisms responsible for this relationship is poorly understood. Platelet abnormalities, autonomic tone, and health behaviors have all been implicated. There exists also the possibility that depression and vascular disease share certain vulnerability genes (McCaffery et al., 2006).
Moreover, it is now apparent that depression aggravates the course of multiple cardiovascular conditions (Glassman et al., 2007) and has regularly been shown to lower adherence to prescribed medication and secondary prevention measures (Glassman et al., 2007b).
Few randomized controlled trials have evaluated the efficacy of treatments for major depression in patients with coronary artery disease.
Depression and cardiovascular disease
* Depression observed following acute coronary syndrome (ACS) is common and associated with an increased risk of mortality. Medically healthy individuals who suffer from depression are at significantly increased risk of developing heart attacks and strokes later in life (Glassman et al., 2007).
* Acute coronary syndrome is both psychologically and physiologically stressful, and it is common to attribute depression observed following ACS to that stress (Glassman et al., 2006)
Furthermore, the Heart rate variability (HRV), a well-recognized measure reflecting fluctuations in autonomic activity, is an independent predictor of death. Earlier studies show that, after myocardial infarction, HRV values increase approximately 50% between 3- and 12-weeks. In post-ACS patients with depression, improvement in HRV could therefore result from the pharmacological action of an antidepressant drug, from an improving mood independent of the drug, or as a result of recovery from the acute cardiac injury.
Depression treatment among patients with coronary artery disease
Few adequately controlled trials evaluated whether antidepressant treatments are either safe or effective in patients with coronary artery disease (CAD). The largest of these, the Sertraline Antidepressant Heart Attack Trial (SADHART) (Glassman et al., 2002) was designed to evaluate the safety and efficacy of sertraline hydrochloride for treatment of MDD in ACS. No adverse cardiovascular effects of sertraline treatment were detected, sertraline was both safe and effective in post-MI depression and observed a reduction in death and recurrent myocardial infarction. Planned subgroup analyses showed a clear benefit of sertraline over placebo for patients with recurrent depression and those with more severe depression.
In addition, the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy, a randomized, controlled, 12-week, parallel-group trial (CREATE) (Lesperance et al., 2007), was the first trial specifically designed to evaluate the short-term efficacy and tolerability of 2 depression treatments in patients with CAD: citalopram, a first-line SSRI antidepressant and interpersonal psychotherapy (IPT), a short-term, manual-based psychotherapy focusing on the social context of depression. The trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for major depression among patients with coronary artery disease and found no evidence of added value of IPT over clinical management. Similar to the results of SADHART CREATE found the benefits of SSRIs for patients with CAD to be clearer for recurrent episodes of major depression than for first episodes.
Clinical implications
* Depression is a painful state, and it should be treated aggressively when indicators of benefit are present; major depression following myocardial infarction is consistently associated with about a 3-fold increase in cardiac mortality and evidence continues to accumulate (Glassman et al., 2007b).
* Major depression severely impairs heart rate variability recovery following an acute coronary event. It is now clear, that depression is also associated with biological changes involving increased heart rate, inflammatory response, plasma norepinephrine, platelet reactivity, absent post-ACS HRV recovery - all of which is associated with life-threatening consequences. It also impairs compliance with doctors advice and health behaviors.
* Based on study results and those of previous trials, the selective serotonin-reuptake-inhibitors (SSRI) citalopram or sertraline plus clinical management should be considered as a first-step treatment for patients with CAD and major depression albeit there is still a clear need for additional studies evaluating interventions to prevent the cardiac prognostic impact of depression.
* From a clinician's point of view, patients with depression after myocardial infarction, especially those with prior episodes, should be both carefully watched and aggressively treated, because they are at an elevated cardiac risk and less likely to get better spontaneousely.
European College of Neuropsychopharmacology
Few randomized controlled trials have evaluated the efficacy of treatments for major depression in patients with coronary artery disease.
Depression and cardiovascular disease
* Depression observed following acute coronary syndrome (ACS) is common and associated with an increased risk of mortality. Medically healthy individuals who suffer from depression are at significantly increased risk of developing heart attacks and strokes later in life (Glassman et al., 2007).
* Acute coronary syndrome is both psychologically and physiologically stressful, and it is common to attribute depression observed following ACS to that stress (Glassman et al., 2006)
Furthermore, the Heart rate variability (HRV), a well-recognized measure reflecting fluctuations in autonomic activity, is an independent predictor of death. Earlier studies show that, after myocardial infarction, HRV values increase approximately 50% between 3- and 12-weeks. In post-ACS patients with depression, improvement in HRV could therefore result from the pharmacological action of an antidepressant drug, from an improving mood independent of the drug, or as a result of recovery from the acute cardiac injury.
Depression treatment among patients with coronary artery disease
Few adequately controlled trials evaluated whether antidepressant treatments are either safe or effective in patients with coronary artery disease (CAD). The largest of these, the Sertraline Antidepressant Heart Attack Trial (SADHART) (Glassman et al., 2002) was designed to evaluate the safety and efficacy of sertraline hydrochloride for treatment of MDD in ACS. No adverse cardiovascular effects of sertraline treatment were detected, sertraline was both safe and effective in post-MI depression and observed a reduction in death and recurrent myocardial infarction. Planned subgroup analyses showed a clear benefit of sertraline over placebo for patients with recurrent depression and those with more severe depression.
In addition, the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy, a randomized, controlled, 12-week, parallel-group trial (CREATE) (Lesperance et al., 2007), was the first trial specifically designed to evaluate the short-term efficacy and tolerability of 2 depression treatments in patients with CAD: citalopram, a first-line SSRI antidepressant and interpersonal psychotherapy (IPT), a short-term, manual-based psychotherapy focusing on the social context of depression. The trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for major depression among patients with coronary artery disease and found no evidence of added value of IPT over clinical management. Similar to the results of SADHART CREATE found the benefits of SSRIs for patients with CAD to be clearer for recurrent episodes of major depression than for first episodes.
Clinical implications
* Depression is a painful state, and it should be treated aggressively when indicators of benefit are present; major depression following myocardial infarction is consistently associated with about a 3-fold increase in cardiac mortality and evidence continues to accumulate (Glassman et al., 2007b).
* Major depression severely impairs heart rate variability recovery following an acute coronary event. It is now clear, that depression is also associated with biological changes involving increased heart rate, inflammatory response, plasma norepinephrine, platelet reactivity, absent post-ACS HRV recovery - all of which is associated with life-threatening consequences. It also impairs compliance with doctors advice and health behaviors.
* Based on study results and those of previous trials, the selective serotonin-reuptake-inhibitors (SSRI) citalopram or sertraline plus clinical management should be considered as a first-step treatment for patients with CAD and major depression albeit there is still a clear need for additional studies evaluating interventions to prevent the cardiac prognostic impact of depression.
* From a clinician's point of view, patients with depression after myocardial infarction, especially those with prior episodes, should be both carefully watched and aggressively treated, because they are at an elevated cardiac risk and less likely to get better spontaneousely.
European College of Neuropsychopharmacology
Cardiovascular Disease Current Events and Cardiovascular Disease News RSSSubstance abuse adds millions to Medicaid's total health care costs
People with substance abuse disorders cost Medicaid hundreds of millions of dollars annually in medical care, suggesting that early interventions for substance abuse could not only improve outcomes but also save substantial amounts of money, according to a comprehensive study that examined records of nearly 150,000 people in six states.
In lung cancer, silencing one crucial gene disrupts normal functioning of genome
While examining patterns of DNA modification in lung cancer, a team of international researchers has discovered what they say is a surprising new mechanism.
University of Maryland researchers identify common gene variant linked to high blood pressure
Researchers at the University of Maryland School of Medicine have identified a common gene variant that appears to influence people's risk of developing high blood pressure, according to the results of a study being published online Dec. 29, 2008 in the Proceedings of the National Academy of Sciences (PNAS).
Brain starvation as we age appears to trigger Alzheimer's
A slow, chronic starvation of the brain as we age appears to be one of the major triggers of a biochemical process that causes some forms of Alzheimer's disease.
Minimizing obesity's impact on ovarian cancer survival
Obesity affects health in several ways, but new research shows obesity can have minimal impact on ovarian cancer survival. A study by researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center found ovarian cancer survival rates are the same for obese and non-obese women if their chemotherapy doses are closely matched to individual weight.
Simple Model Predicts Those at Risk for Chronic Kidney Disease
Traditionally, doctors have had no clear way to predict which of their patients might be headed down the road to chronic kidney disease (CKD).
Biomarkers improve ischemic stroke prediction
Testing patient's blood for two proteins or biomarkers that occur when inflammation is present could help doctors identify which patients are more likely to have a stroke, said researchers at Baylor College of Medicine in Houston in a report that appears online in the journal Stroke.
Patients with severe psoriasis need evaluation of heart disease risk
According to new recommendations in the December 10 issue of The American Journal of Cardiology (AJC), published by Elsevier, new research is called for and patients with severe forms of the skin disease psoriasis should receive evaluation and possible treatment to reduce their risk of coronary artery disease (CAD).
Surge in older cancer survivors expected as baby boomers age
The United States could be faced with a national health care crisis in the coming decades as the country's baby boomer population ages and a growing number of older adults find themselves diagnosed with and living longer with cancer.
New study finds not all fats are created equal
Eating saturated fats from butter, cream and meat, as well as trans fats found in hydrogenated oils can boost our risk of cardiovascular disease, while consuming mono-unsaturated fat can be good for our heart.
More Cardiovascular Disease Current Events and Cardiovascular Disease News Articles
 | Reverse Heart Disease Now: Stop Deadly Cardiovascular Plaque Before It's Too Late by Sinatra, James C., M.D. Roberts While most books focus solely on the role of cholesterol in heart disease, Reverse Heart Disease Now draws on new research that points to the surprising other causes. Two leading cardiologists draw on their collective fifty years of clinical cardiology research to show you how to combine the benefits of modern medicine, over-the-counter vitamins and supplements, and simple lifestyle changes to... |
 | Cardiovascular Disease in the Elderly (Contemporary Cardiology) A panel of clinicians, researchers, and leaders in the field review and discuss the latest findings on the pathophysiology, diagnosis, and management of cardiovascular disease in the older patient. The authors explain the physiological changes associated with the normal aging process that may lead to the development of disease, to adverse consequences once disease develops, and which alter the... |
 | Pollock's Textbook of Cardiovascular Disease and Rehabilitation Pollock's Textbook of Cardiovascular Disease and Rehabilitation honors the legacy of the late Michael L. Pollock, PhD (1936-1998). Pollock, an innovative and influential cardiac researcher and clinician, was highly regarded for his substantial educational and scientific contributions to the field of exercise science and sports medicine. This text presents an approach to cardiovascular disease... |
 | Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume (Heart Disease (Braunwald) (Single Vol)) by Peter Libby, Robert O. Bonow, Douglas L. Mann, Douglas P. Zipes Dr. Braunwald's masterwork returns ... bringing you the definitive guidance you need to overcome any challenge in clinical cardiology today, using the best approaches available! Hundreds of world authorities, many of them new to this edition, synthesize all of the recent developments that are revolutionizing practice - from the newest findings in molecular biology and genetics to the latest... |
 | Cardiovascular Nutrition: Disease Management And Prevention This new resource thoroughly examines the role of nutrition in the management and prevention of cardiovascular disease. Written and reviewed by leading physicians and registered dietitians in cardiovascular practice, this comprehensive publication includes: risk factors and nutrition assessment, lifestyle counseling strategies for behavior change, the role of functional foods, antioxidants and... |
 | Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty Harvard Medical School, Boston, MA. Textbook on diseases of the cardiovascular system. For medical students and residents. Halftone illustrations. 32 U.S. contributors. Previous edition: c1993. Softcover. DNLM: Heart... |
 | Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set by Eugene Braunwald With 35 new chapters as well as comprehensive updates throughout, the New Edition of the cardiology masterwork represents the most complete revision to date. Hundreds of world authorities synthesize all of the developments that are revolutionizing practicefrom the newest findings in molecular biology and genetics to the latest imaging modalities, interventional procedures, and medications. Plus,... |
 | Cardiovascular Disease in Small Animal Medicine by Wendy A. Ware This is a comprehensive, authoritative yet user friendly guide to cardiovascular diseases and disorders in the dog and cat. It is fully referenced and richly illustrated throughout by clinical colour photos, imaging and diagrams of the highest quality. Coverage includes evaluation techniques, investigative procedures, diagnosis, medical and surgical management options and methods. Dr. Ware’s... |
| Aortic Diseases: Clinical Diagnostic Imaging Atlas with DVD (Cardiovascular Emergencies: Atlas and Multimedia) by Stuart J. Hutchison The number of cases of aortic disease is on the rise. In fact, 20,000 patients in the United States died from abdominal aortic aneurysms alone. Now, you can detect and treat the many complications associated with aortic disease in time to save many more patients. This title in the brand-new Clinical Diagnostic Imaging Atlas Series offers you authoritative guidance from a well-known cardiologist... | |
 | Taylor's Cardiovascular Diseases: A Handbook This handbook, edited by Dr. Robert Taylor, deals with cardiovascular problems that primary clinicians often find difficult to diagnose or treat. Each chapter discusses areas in which the reader gains in-depth knowledge on complex terms (such as hypertension, ischemic heart disease, and cardiovascular emergencies). Also unique to the handbook is its extensive coverage of cerebrovascular disease,... |
| © 2009 BrightSurf.com |